{
    "nctId": "NCT02062489",
    "briefTitle": "Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients",
    "officialTitle": "N/A",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 688,
    "primaryOutcomeMeasure": "Disease-free survival of patients",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients signed the written informed consent\n* The patients present with operable unilateral invasive breast cancers without distant metastasis(stage I, II, and III)\n* The breast tumor's positive ER/PR rate is \\<1%, and positive ER-beta1 rate is \u226510% by IHC.\n* The patients have no history of neoadjuvant hormone therapy.\n* The patients have normal cardiac functions by echocardiography.\n* The patients' ECOG scores are \u22640-2.\n* Female patient who is \u2265 18yrs, and \u2264 70yrs.\n* The patients are non-pregnant, and disposed to practice contraception during the whole trial.\n* The patients underwent neoadjuvant chemotherapy plus surgery or directly modified radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or axillary lymph node dissection) after diagnosis of breast cancer.\n* The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin) after surgery according to the 2013 NCCN guideline.\n* The results of patients' blood tests are as follows:\n\nHb\u226590g/L; WBC\u22654.0\u00d7109/L; Plt\u2265100\u00d7109/L; Neutrophils\u22651.5\u00d7109/L; ALT and AST \u2264 triple of normal upper limit; TBIL \u2264 1.5 times of normal upper limit; Creatinine \u2264 1.25 times of normal upper limit.\n\nExclusion Criteria:\n\n* The patients have other cancers at the same time or have the history of other cancers except controlled skin basal cell carcinoma or skin squamous cell carcinoma or carcinoma in situ of cervix uterus;\n* The patients have active infections that were not suitable for chemotherapy;\n* The patients have severe non-cancerous diseases.\n* The patients have history of neoadjuvant hormone therapy.\n* The patients have bilateral breast cancers or DCIS or metastatic breast cancers.\n* The patients are undergoing current administration of anti-cancer therapies, or are attending other clinical trials.\n* The patients are pregnant or lactational, or they refuse to practice contraception during the whole trial.\n* The patients are in some special conditions that they can't understand the written informed consent, such as they are demented or hawkish.\n* The patients have allergic history or contraindication of tamoxifen.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}